readthroughSign in
Nov 16, 2026Clinical readout

iBio reports new preclinical data on obesity candidate IBIO-610 and amylin program

Extended non-human primate data on IBIO-610 and rodent amylin findings were presented or set for presentation at ObesityWeek, PEGS Europe and an amylin therapeutics summit.

iBio, Inc. announced on November 16, 2026 that it had presented extended preclinical data on its Activin E antibody candidate IBIO-610 at ObesityWeek 2026, with additional amylin program findings slated for PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.

The IBIO-610 data came from an obese non-human primate study including five animals on IBIO-610 and six on vehicle, with IBIO-610 initially administered every eight weeks, followed by more frequent dosing and a dose-free period.1 The observation period was extended through week 28. By that point, the IBIO-610 group showed a 2.3% reduction in body weight relative to vehicle, with change in body weight first observed around week 18.1 At week 24, total fat was 9.6% lower, abdominal subcutaneous fat was 16.6% lower and visceral fat was 10.96% lower relative to vehicle, while lean mass was generally maintained.1 The company also reported near-complete suppression of active Activin E through week 28.1

On the amylin program, iBio said the program combines a receptor-targeting antibody with a fused peptide agonist and demonstrated highly selective activation of amylin receptors 1 and 3.1 In vitro, the antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone.1 In a rodent study, rats dosed with the company's selective amylin receptor agonist had reduced food intake over 24 hours compared with vehicle.1

iBio stated it plans to advance selective amylin receptor agonists into further preclinical studies in diet-induced obesity models.1 Presentations are scheduled at ObesityWeek on November 15, PEGS Europe on November 19, and the Amylin-Based Therapeutics Summit on December 1 and 2, 2026.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.